Anchor, Kyowa Hakko Kirin collaborate on pepducin tech for GPCR targets

Wednesday, August 1, 2012 11:15 AM

Anchor Therapeutics, a developer of pepducin technology, has entered into a collaborative agreement with Kyowa Hakko Kirin (KHK), a Japanese biopharmaceutical company, to advance KHK’s internal G protein-coupled receptor (GPCR) drug discovery portfolio.

The agreement takes advantage of Anchor’s expanded business strategy to offer its pepducin technology for use as in vitro and in vivo research tools, in addition to developing pepducin therapeutics.

Anchor and KHK will work jointly to discover and optimize pepducin research tools to further the molecular understanding of certain GPCR targets in the KHK portfolio. KHK will assume responsibility for application of the research tools against the targets. Anchor will receive an upfront payment, research funding, and downstream milestones.

“We are excited about this initial application of the pepducin technology as research tools and believe that this agreement will provide KHK with a unique perspective to better evaluate their GPCR targets and advance their internal drug discovery efforts,” said Thomas J. McMurry, interim president and senior vice president, R&D, Anchor Therapeutics. “The licensing of pepducin technology as a research tool is a fundamental component of our business strategy, and we are actively pursuing other collaborations with pharmaceutical and biotechnology companies and research institutions.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs